Elexacaftor
Elexacaftor, also known as VX-445 and WHO 11180, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor (VX-445–tezacaftor–ivacaftor).
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Elexacaftor |
|---|---|
| Iupac 化学名称 | (S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide |
| 同义词 | Elexacaftor, WHO 11180; WHO 11180; WHO11180; VX-445; VX 445; VX445; Trikafta. |
| 英文同义词 | Elexacaftor, WHO 11180; WHO 11180; WHO11180; VX-445; VX 445; VX445; Trikafta. |
| 分子式 | C26H34F3N7O4S |
| 分子量 | 597.6582 |
| Smile | O=C(C1=CC=C(N2N=C(OCC(C)(C)C(F)(F)F)C=C2)N=C1N3C(C)(C)C[C@H](C)C3)NS(=O)(C4=CN(C)N=C4C)=O |
| InChiKey | MVRHVFSOIWFBTE-INIZCTEOSA-N |
| InChi | InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1 |
| Cas号 | 2216712-66-0 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 干燥、黑暗，短期（日至周）在0-4摄氏度，长期（月至年）在-20摄氏度。 |
| 可溶性 | 可溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周。 |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee
CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of
triple-combination CFTR modulators for cystic fibrosis patients with one or two
F508del alleles. ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi:
10.1183/23120541.00082-2019. eCollection 2019 Apr. PubMed PMID: 31218221; PubMed
Central PMCID: PMC6571452.
2: Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe
SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C,
Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two
Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi:
10.1056/NEJMoa1807120. Epub 2018 Oct 18. PubMed PMID: 30334692; PubMed Central
PMCID: PMC6289290.
